Additionally, a reduction in cisplatin’s cytotoxicity, accumulation, survival, and increased resistance has occurred in colorectal, head, and neck cancers when OCT3 activity was suppressed, and in lung cancer when OCT6 expression was restricted. Here, SLC22A3 is linked to head and neck cancer.